| TLR9-antagonists | Class | Properties |
---|---|---|---|
4084-F | CCT GGA TGG GAA | B | 5' linear, shortest active |
INH-1 | CCT GGA TGG GAA TTC CCA TCC AGG | R | 5' palindrome |
INH-18 | CCT GGA TGG GAA CTT ACC GCT GCA | B | 5' linear |
INH-43 | CCT GGA TAA AAA TTT TTA TCC AGG | R | Lacks GGG |
INH-44 | CCT GAA TAA AAA CTT ACC GCT GCA | B | Lacks GGG |
INH-45 | TAT GGA TGG GAA TTC CCA TCC ATA | R | Lacks CCT |
INH-46 | TAT GGA TGG GAA CTT ACC GCT GCA | B | Lacks CCT |
INH-47 | TAT GGA TTT TAA TTA AAA TCC ATA | R | Lacks CCT/GGG |
INH-48 | TAT GGA TTT TAA CTT ACC GCG GCA | B | Lacks CCT/GGG |
5' OVHG-short | CCT GGA TGG GAA TTC CCA TCC | R | 5' short overhang (3 nucleotide OVHG) |
5' OVHG-scr. short | CCT GGA TGG GAA CTT ACC GCT | B | 5' linear |
5' OVHG-medium | CCT GGA TGG GAA TTC CCA | R | 5' medium overhang (6 nucleotide OVHG) |
5' OVHG-scr. medium | CCT GGA TGG GAA CTT ACC | B | 5' linear |
5' OVHG-long | CCT GGA TGG GAA TTC | R | 5' long overhang (9 nucleotide OVHG) |
5' OVHG-scr. long | CCT GGA TGG GAA CTT | B | 5' linear |
INH-4 3' palindrome | TTC CCA TCC AGG CCT GGA TGG GAA | R | 3' palindrome |
INH-13 3' scr. pal. | CTT ACC GCT GCA CCT GGA TGG GAA | B | 3' linear |
3' OVHG-short | CCA TCC AGG CCT GGA TGG GAA | R | 3' short overhang (3 nucleotide OVHG) |
3' OVHG-scr. short | ACC GCT GCA CCT GGA TGG GAA | B | 3' linear |
3' OVHG-medium | TCC AGG CCT GGA TGG GAA | R | 3' medium overhang (6 nucleotide OVHG) |
3' OVHG-scr. medium | GCT GCA CCT GGA TGG GAA | B | 3' linear |
3' OVHG-long | AGG CCT GGA TGG GAA | R | 3' long overhang (9 nucleotide OVHG) |
3' OVHG-scr. long | GCA CCT GGA TGG GAA | B | 3' linear |
4173 | RRR RRR RRR RRR RRR | B | Linear control, R = random |
 | TLR9-agonists | Class | Properties |
CpG-2336 | ggGGACGACGTCGTGgggggg | A(D) | Lowercase PS linkages |
CpG-1826 | TCC ATG ACG TTC CTG ACG TT | B(K) | Linear, murine |
CpG-2006 | TCG TCG TTT TGT CGT TTT GTC GTT | B(K) | Linear, human |